A clinical trial to look at how well different targeted therapies work to treat metastatic colorectal cancer (mCRC)

A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (Intrinsic)

  • Cancer
  • Colorectal Cancer (CRC)
  • Metastatic Colorectal Cancer
Please note that the recruitment status of the trial at your site may differ from the overall study status because some study sites may recruit earlier than others.
Trial Status:

Recruiting

This trial runs in
Countries
  • Australia
  • Canada
  • Denmark
  • France
  • Germany
  • Italy
  • Poland
  • South Korea
  • Spain
  • Taiwan
  • United Kingdom
  • United States
Trial Identifier:

NCT04929223 2021-001207-33 2023-505163-37-00 WO42758

      Show trial locations

      The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical trial see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.

      The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

      Results Disclaimer

      Trial Summary

      This open-label, exploratory study is designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or combinations, in participants with metastatic colorectal cancer (mCRC) whose tumors are biomarker positive as per treatment arm-specific definition. Eligible participants with mCRC will be enrolled into specific treatment arms based on their biomarker assay results.

      Hoffmann-La Roche Sponsor
      Phase 1 Phase
      NCT04929223, WO42758, 2021-001207-33,2023-505163-37-00 Trial Identifier
      All Gender
      ≥18 Years Age
      No Healthy Volunteers

      1. Why is the INTRINSIC clinical trial needed?

      Metastatic colorectal cancer (mCRC) is a type of colorectal cancer that has spread to other parts of the body outside of the colorectal area. This trial aims to test the safety and effectiveness of multiple therapies for the treatment of mCRC and to understand how the body responds to these treatments. These new therapies target specific changes or genetic alterations (changes in a person’s DNA) in an individual’s tumour. As the trial progresses, the safety and effectiveness of other new treatment options may be tested in individuals with mCRC with different changes or genetic alterations.

      2. How does the INTRINSIC clinical trial work?

      This clinical trial is recruiting people who have been diagnosed with metastatic colorectal cancer. People who take part in this clinical trial will be given the clinical trial treatment for as long as it can help them. The clinical trial doctor will see participants regularly. The number of visits the participants will have will depend on which treatment group they are in. These hospital visits will include checks, such as a tumour assessment scan, to see how the participant responds to treatment and any side effects they may have. The tumour assessment scans will occur every 6 or 8 weeks for the first 48 weeks of the trial and then every 8 or 12 weeks after that. Participants’ total time in the clinical trial will depend on how they tolerate treatment and how their cancer responds to treatment, this could be as long as 2 years or more. Participants can stop trial treatment and leave the clinical trial at any time.

      3. What are the main endpoints of the INTRINSIC clinical trial?

      The main clinical trial endpoint (the main result measured in the trial to see if the drug has worked) is to determine how many participants have a reduction in the size of their tumour (known as the “objective response rate”). The other clinical trial endpoints include:

      • How much time there is between the participant’s cancer first responding to treatment and the cancer getting worse (known as “duration of response”)
      • How many participants have tumours that stay the same or reduce in size for at least 12 weeks (known as “disease control rate”)
      • The number and seriousness of any side effects, and
      • How the body processes the different therapies

      4. Who can take part in this clinical trial?

      People can take part in this trial if they have been diagnosed with mCRC that has certain genetic features and are at least 18 years old. People may not be able to take part in this trial if they have received anti-cancer treatment within 2 weeks of starting the clinical trial, or another clinical trial treatment within 28 days of starting this clinical trial. People who are pregnant or breastfeeding, are intending to become pregnant during the clinical trial or up to about 6 months after treatment, or who have certain other medical conditions or are taking certain treatments, are not able to take part. There are other specific criteria that participants may need to meet for each treatment in this clinical trial.

      5. What treatment will participants be given in this clinical trial?

      Everyone who joins this clinical trial will enter one of seven trial cohorts:

      • Cohort 1: If a participants’ mCRC has a specific genetic alteration in the KRAS gene, and they have not previously had chemotherapy that contained oxaliplatin, they will be given divarasib as a pill (to be swallowed) once every day, as well as cetuximab plus FOLFOX, each given as an infusion once every 2 weeks
      • Cohort 2: If a participants’ mCRC has a specific genetic alteration in the KRAS gene, and their cancer was not effectively controlled by, they did not tolerate, or they refused to be given oxaliplatin-and/or irinotecan-containing chemotherapy, they will be given divarasib as a pill (to be swallowed) once every day, as well as cetuximab as an infusion once every 2 weeks
      • Cohort 3: If a participants’ mCRC has a specific genetic alteration in the KRAS gene, and they have not previously had chemotherapy that contained irinotecan, they will be given divarasib as a pill (to be swallowed) once every day, as well as cetuximab plus FOLFIRI each given as an infusion once every 2 weeks
      • Cohort 4: If a participant has “microsatellite instability-high” (MSI-H) mCRC, which means that a lot of instability has been detected in their mCRC (due to defects in the proteins responsible for repairing DNA), they will be split into two groups randomly (like flipping a coin) and given either atezolizumab plus tiragolumab plus bevacizumab, each given as an infusion (into a vein) once every 3 weeks OR atezolizumab plus tiragolumab, both given as an infusion once every 3 weeks
      • Cohort 5 (participants in the United States only): If a participants’ mCRC has specific genetic alterations in the BRAF gene, they will be given SY-5609 as a pill (to be swallowed) once every day for 7 days, followed by 7 days off, as well as atezolizumab as an infusion once every 4 weeks
      • Cohort 6: If a participants’ mCRC has genetic alterations in the PIK3CA gene, they will be given inavolisib as a pill (to be swallowed) once every day, as well as cetuximab as an infusion once every week
      • Cohort 7: If a participants’ mCRC has genetic alterations in the PIK3CA and RAS genes, they will be given inavolisib as a pill (to be swallowed) once every day, as well as bevacizumab as an infusion once every 3 weeks

      This is an open-label trial, which means everyone involved, including the participant and the clinical trial doctor, will know the clinical trial treatment the participant has been given.

      6. Are there any risks or benefits in taking part in this clinical trial?

      The safety or effectiveness of the experimental treatment or use may not be fully known at the time of the trial. Most trials involve some risks to the participant. However, it may not be greater than the risks related to routine medical care or the natural progression of the health condition. People who would like to participate will be told about any risks and benefits of taking part in the clinical trial, as well as any additional procedures, tests, or assessments they will be asked to undergo. All of these will be described in an informed consent document (a document that provides people with the information they need to decide to volunteer for the clinical trial).

      Risks associated with the clinical trial drugs

      Participants may have side effects (an unwanted effect of a drug or medical treatment) from the drugs used in this clinical trial. Side effects can be mild to severe, even life-threatening, and vary from person to person. Participants will be closely monitored during the clinical trial and safety assessments will be performed regularly. Participants will be told about the known side effects of atezolizumab, tiragolumab, bevacizumab,
      SY-5609, inavolisib, divarasib, cetuximab, FOLFOX, and FOLFIRI      , and possible side effects based on human and laboratory studies or knowledge of similar drugs. Atezolizumab, tiragolumab, bevacizumab, cetuximab, FOLFOX, and FOLFIRI will each be given as an intravenous infusion (injection into a vein). Participants will be told about any known side effects of intravenous infusion. SY-5609, inavolisib, divarasib will each be given as a pill (to be swallowed). Participants will be told about any known side effects of oral administration.

      Potential benefits associated with the clinical trial

      Participants' health may or may not improve from participation in the clinical trial. Still, the information collected may help other people with similar medical conditions in the future.

      Trial Summary

      This open-label, exploratory study is designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or combinations, in participants with metastatic colorectal cancer (mCRC) whose tumors are biomarker positive as per treatment arm-specific definition. Eligible participants with mCRC will be enrolled into specific treatment arms based on their biomarker assay results.

      Hoffmann-La Roche Sponsor
      Phase 1 Phase
      NCT04929223, WO42758, 2021-001207-33,2023-505163-37-00 Trial Identifier
      Inavolisib, Bevacizumab, Cetuximab, Atezolizumab, Tiragolumab, SY-5609, Divarasib, FOLFOX, FOLFIRI Treatments
      Metastatic Colorectal Cancer Condition
      Official Title

      A Phase I/Ib Global, Multicenter, Open-label Umbrella Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

      Eligibility Criteria

      All Gender
      ≥18 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Signed cohort-specific Informed Consent Form
      • Age >= 18 years at time of signing Informed Consent Form
      • Biomarker eligibility as determined by:
      • A validated test approved by local health authorities for detection of the specified biomarkers/mutations.
      • A validated test performed at a College of American Pathologists/clinical laboratory improvement amendments (CAP/CLIA) -certified or equivalently accredited diagnostic laboratory using a validated test for detection of the specified biomarkers.
      • Prior test results completed before signing cohort-specific Informed Consent Form or local test results generated prior to or during screening, and availability of a full report of the testing results OR
      • Blood-based FoundationOne Liquid CDx biomarker eligibility test result generated prior to or during screening or, in case of re-enrollment after treatment discontinuation, prior to starting a new anti-cancer therapy.
      • Eastern Cooperative Oncology Group (ECOG) Performance Status of <= 1
      • Life expectancy >= 3 months, as determined by the investigator
      • Histologically confirmed adenocarcinoma originating from the colon or rectum
      • Metastatic disease
      • Prior therapies for metastatic disease
      • Ability to comply with the study protocol, in the investigators judgment
      • Measurable disease (at least one target lesion) according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)
      • Baseline tumor tissue samples will be collected from all participants for exploratory biomarker research
      • Adequate hematologic and organ function within 14 days prior to initiation of study treatment
      • For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures
      • For men: agreement to remain abstinent or use contraceptive measures, and agreement to refrain from donating sperm
      Exclusion Criteria
      • Current participation or enrollment in another interventional clinical trial. Participants who are participating in the follow-up period of an interventional clinical trial are eligible for the study.
      • Any systemic anti-cancer treatment within 2 weeks or 5 half-lives (whichever is shorter) prior to start of study treatment
      • Treatment with investigational therapy within 28 days prior to initiation of study treatment
      • Pregnant or breastfeeding, or intending to become pregnant during the study
      • History of or concurrent serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the patient's safe participation in and completion of the study or confounds the ability to interpret data from the study
      • Severe infection within 4 weeks prior to initiation of study treatment or any active infection that, in the opinion of the investigator, could impact patient safety
      • Incomplete recovery from any surgery prior to the start of study treatment that would interfere with the determination of safety or efficacy of study treatment
      • Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently)
      • Uncontrolled tumor-related pain
      • Uncontrolled or symptomatic hypercalcemia
      • Clinically significant and active liver disease
      • Negative HIV test at screening, with the following exception: Participants with a positive HIV test at screening are eligible provided they are stable on anti-retroviral therapy for at least 4 weeks, have a CD4 count greater than or equal to 200/uL, have an undetectable viral load, and have not had a history of opportunistic infection attributable to AIDS within the last 12 months.
      • Symptomatic, untreated, or actively progressing CNS metastases
      • History of leptomeningeal disease or carcinomatous meningitis
      • History of malignancy other than CRC within 2 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death
      • Any other disease, unresolved toxicity from prior therapy, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug, may affect the interpretation of the results, or may render the participant at high risk from treatment complications
      • Requirement for treatment with any medicinal product that contraindicates the use of any of the study treatments, may interfere with the planned treatment, affects participant compliance, or puts the patient at higher risk for treatment-related complications

      For the latest version of this information please go to www.forpatients.roche.com

       

      Related Trials

      Use our search to find other trials on ForPatients in related disease areas.

      Colorectal Cancer (CRC) Metastatic Colorectal Cancer

      Clinical Research Explained

      Information about what clinical trials and observational studies are. Understand why you might want to take part in clinical research and why diversity in clinical research is important.

      Find out now